Skip to content
EU Startups News
  • Funding
  • Launch
  • Partnership
  • Acquisition
  • Policy
  • Exit & IPO

Phosphoenix

Amsterdam Neuroprosthetics Startup Phosphoenix Secures €1.3M to Advance Blindness Treatment

September 18, 2026 by Marco Bianchi

Amsterdam‑based MedTech startup Phosphoenix secured €1.3 million to advance its brain‑implant neuroprosthesis aimed at restoring functional vision for people with profound blindness, moving toward a first‑in‑human trial and a future Series A round.

Categories Funding Tags €1M–€5M, Healthtech, Netherlands, Phosphoenix, Pre-seed Leave a comment
Browse by Country

Latest

Munich-based Quint Computing Secures €11.3 Million to Scale Quantum Processor TechnologyNov 3, 2026
Lithuanian RegTech Startup AMLYZE Partners with Mano Bank on AML Compliance PlatformNov 3, 2026
Berlin-Based Robin Capital Closes Second Fund at €15 Million, Doubling Its Early-Stage War ChestNov 3, 2026
Quantum Italia Backs Milan Post-Quantum Cryptography Startup Promethence with €200,000 InvestmentNov 3, 2026
Helsinki-Tallinn Railway Tunnel Project Advances with Estonian Planning Application and New Infrastructure FundNov 3, 2026

EU Markets

European Markets Flash Caution Signals: What This Week's Financial Turbulence Means for Startup FoundersOct 30, 2026
European Startups, Brace Yourselves: Rate Pressures, AI Disruption, and a €550M Legal Tech Unicorn Define This Week's Financial LandscapeOct 23, 2026
French Debt Fears, AI Tailwinds, and a New Unicorn: What Europe's Financial Markets Mean for Your Startup This WeekOct 16, 2026
European Markets Flash Warning Signs and Green Lights for Startups This WeekOct 9, 2026

EU Startups News
• About Us • Privacy Policy

Follow Us

LinkedIn X / Twitter Facebook

Stay informed

Get the latest European startup news delivered to your inbox every week. For broader markets news, visit: EU Finance News

No spam. Unsubscribe anytime.

By continuing to use this site you agree to our Privacy Policy and the use of cookies.

© 2026 EU Startups News • Built with GeneratePress

By continuing to use this site you agree to our Privacy Policy and the use of cookies.